Physician profile
Michael Lasser
NPI 1821081399
$1,890.87
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $362 · 2021: $759 · 2022: $201 · 2023: $42.06 · 2024: $37.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $659.27 | 2019-2022 | |
| Tris Pharma INC | $176.08 | 2019-2021 | |
| Pfizer INC. | $133.16 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $125.02 | 2019-2022 | |
| Adlon Therapeutics L.P. | $102.62 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.25 | 2019-2022 | |
| Sobi, INC | $87.69 | 2019-2021 | |
| Novo Nordisk INC | $83.33 | 2019 | |
| Galderma Laboratories, L.P. | $76.26 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $72.36 | 2021-2024 | Qelbree |
| Janssen Biotech, INC. | $71.14 | 2021-2022 | |
| Kaleo, INC. | $64.57 | 2019-2021 | |
| Sanofi Pasteur INC. | $32.90 | 2021 | |
| Corium, LLC | $23.59 | 2023 | Azstarys |
| Shire North American Group INC | $21.90 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.16 | 2019 | |
| Nestle Healthcare Nutrition INC. | $19.05 | 2021 | |
| Dentsply Ih INC. | $13.67 | 2021 | |
| Arbor Pharmaceuticals, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.